Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03954015 · ClinicalTrials.gov registry record · Early Phase 1
Comparison of Three Methods for Early Detection of Breast Cancer
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT03954015: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT03954015 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03954015, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Subjects with suspicious breast lesion (BIRADS category 4/5) who are scheduled to undergo biopsy will be recruited to undergo imaging evaluation with Contrast Enhanced Dual Energy Mammography (CEDM), Contrast Enhanced Breast MR (CEMR) and Contrast Enhanced Ultrasound (CEUS).
Interventions
- DRUG Lumason
- DIAGNOSTIC_TEST Contrast Enhanced imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2021-10-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03954015
The ClinicalTrials.gov registry entry for NCT03954015 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lumason is the first listed.
NCT03954015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03954015 about?
NCT03954015 is a clinical study titled "Comparison of Three Methods for Early Detection of Breast Cancer". Subjects with suspicious breast lesion (BIRADS category 4/5) who are scheduled to undergo biopsy will be recruited to undergo imaging evaluation with Contrast Enhanced Dual Energy Mammography (CEDM), Contrast Enhanced Breast MR (CEMR) and Contrast Enhanced Ultrasound (CEUS).
What is the current status of trial NCT03954015?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2019-10-15. Estimated completion is 2021-10-05.
What interventions are being tested in trial NCT03954015?
The interventions under investigation include: Lumason (DRUG), Contrast Enhanced imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03954015?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.